Encorafenib (Braftovi)
Canadian Journal of Health Technologies · 30.04.2026 · 6 (4)
DOI: 10.51731/cjht.2026.1429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 30.04.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Encorafenib (Braftovi), 75 mg capsules taken orally. Indication: Encorafenib, in combination with cetuximab and mFOLFOX6, for the treatment of patients with mCRC with a BRAF V600E mutation, as detected by a validated test.
Zitieren
APA
CDA-AMC (2026). Encorafenib (Braftovi). Canadian Journal of Health Technologies, 6(4). https://doi.org/10.51731/cjht.2026.1429
Vancouver
CDA-AMC. Encorafenib (Braftovi). Canadian Journal of Health Technologies. 2026;6(4). doi:10.51731/cjht.2026.1429
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Encorafenib (Braftovi)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {4},
doi = {10.51731/cjht.2026.1429}
}
EUVIMED